BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., today announced that it has formed a collaboration with Repare Therapeutics, a leading clinical-stage precision oncology company, to provide prospective genomic profiling to patients in Repare’s ongoing Phase I/Ib MYTHIC study (NCT04855656) of lunresertib alone or in combinations in genomically-defined patient populations. The companies are also exploring opportunities to develop FoundationOne®CDx, a tissue-based comprehensive genomic profiling test, as a companion diagnostic for the lunresertib program.
BURNABY, British Columbia, June 06, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; PMV Pharma) today announced a partnership to develop Foundation...
Foundation Medicine Announces Details of Over 20 Presentations at the 2024 ASCO® Annual Meeting
Foundation Medicine Launches RNA Sequencing Test, FoundationOne®RNA, in the U.S.
Foundation Medicine Announces Details of Presentations at AACR Annual Meeting
Foundation Medicine Appoints Dan Malarek as Chief Executive Officer
AnHeart Therapeutics and Foundation Medicine Announce Collaboration
Foundation Medicine Announces Collaboration with Pierre Fabre Laboratories